Christina Ackermann Joins Verona Pharma as Non-Executive Director
31 8월 2023 - 3:00PM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces
effective September 1, 2023, Ms. Christina Ackermann will join the
board as a Non-Executive Director.
Ms. Ackermann brings over 25 years of legal and
management experience across the pharmaceutical, device and
consumer products industries. Most recently, she served as
Executive Vice President, General Counsel and Global President
Ophthalmic Pharmaceuticals at Bausch + Lomb Corporation where she
was responsible for strategic planning and worldwide
commercialization of pharmaceutical prescription assets across the
portfolio as well as global legal affairs. Previously, Ms.
Ackermann was part of the Novartis group of companies for 14 years
where she served in multiple leadership roles of increasing
responsibility including Global Head, Legal and General Counsel of
Alcon and Sandoz. Earlier in her career, Ms. Ackermann held
Associate General Counsel roles at both Bristol-Myers Squibb and
DuPont Pharmaceuticals.
“We are pleased to welcome Christina to the
Board,” said Dr. David Ebsworth, Chairperson of Verona Pharma. “Her
broad expertise and leadership across commercial, legal affairs and
compliance will be key as we prepare for the potential
commercialization of ensifentrine.”
Ms. Ackermann currently serves as a
Non-Executive Director on the board of Oculis Holding AG. She holds
a Post Graduate Diploma in EC Competition Law from King’s College
at the University of London, UK, and a LLB from Queen’s University,
Kingston, Canada.
For further information please contact:
|
|
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel:
+1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to be the first non-steroidal
therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one compound.
The Company has evaluated nebulized ensifentrine in its Phase 3
clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the second quarter of 2023, Verona Pharma submitted a New Drug
Application (“NDA”) to the US Food and Drug Administration (“FDA”)
for ensifentrine for the maintenance treatment of patients with
COPD.Two additional formulations of ensifentrine have been
evaluated in Phase 2 trials for the treatment of COPD: dry powder
inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”).
Ensifentrine has potential applications in cystic fibrosis, asthma
and other respiratory diseases. For more information, please visit
www.veronapharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements contained in this press release that do
not relate to matters of historical fact should be considered
forward-looking statements. These forward-looking statements are
based on management's current expectations. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance, or achievements to be materially
different from our expectations expressed or implied by the
forward-looking statements. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024